Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
Eli Lilly and Company (NYSE: LLY) today announced data from a Phase III trial comparing the effects of FORTEO^® (teriparatide [rDNA origin] injection) and risedronate on back pain in postmenopausal women with osteoporotic vertebral fractures. The study showed no difference between FORTEO and risedronate on the primary endpoint of at least a 30 percent reduction in worst back pain from baseline to six months of therapy, as assessed by a numeric rating scale in each treatment group. However, there were statistically significant differences in favor of FORTEO in some exploratory measures, including greater increases in bone mineral density (BMD) and fewer patients with new vertebral fractures. The results of the study are published in the August issue of Osteoporosis International.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.